UAE

The United Arab Emirates operates a multi-tiered regulatory framework for health products, governed primarily by the Ministry of Health and Prevention (MOHAP) at the federal level, alongside the Dubai Health Authority (DHA) and the Department of Health Abu Dhabi (DOH) as emirate-level authorities with overlapping jurisdiction. The principal legislative foundation includes Federal Law No. 4 of 1983 concerning the pharmaceutical profession, Federal Law No. 7 of 2016 on medical devices, and associated Cabinet resolutions and ministerial decisions that define registration, post-market surveillance, and compliance obligations. All health products, including pharmaceuticals, medical devices, in-vitro diagnostics, and digital health solutions, must obtain registration or listing approval from the relevant authority before being placed on the UAE market, with MOHAP serving as the primary federal gateway for products distributed across multiple emirates.

Applicants are required to appoint a UAE-registered local agent or sponsor to submit and maintain product dossiers on behalf of the manufacturer. MOHAP accepts submissions structured according to the Common Technical Document (CTD) format for pharmaceuticals and the Global Medical Device Nomenclature (GMDN) framework for devices, and it recognizes approvals from reference regulatory agencies such as the US FDA, EMA, Health Canada, and comparable stringent authorities to facilitate expedited review. The UAE has actively pursued regulatory modernization in recent years, including the launch of the MOHAP eServices portal, alignment with the International Medical Device Regulators Forum (IMDRF) guidance for devices and diagnostics, and the introduction of a unified digital health regulatory framework under the National Digital Health Strategy, requiring conformity assessments and cybersecurity attestations for software-based health solutions.

Public procurement of health products in the UAE is decentralized across federal and emirate-level entities, reflecting the country's federated governance structure. At the federal level, MOHAP procures pharmaceuticals, devices, and consumables for federal health facilities through centralized tendering processes managed in coordination with the Federal Authority for Government Human Resources and the Ministry of Finance. Each emirate maintains its own procurement mechanism: Abu Dhabi's Department of Health and the Abu Dhabi Public Health Centre oversee sourcing for the Thiqa and Daman insurance networks, while the Dubai Health Authority manages procurement for DHA-operated facilities through its own tender board. The Health Authority of Sharjah and equivalent bodies in the Northern Emirates conduct independent procurement processes, resulting in suppliers often needing to engage multiple authorities to achieve broad market access across the country.

The private sector constitutes a significant and growing proportion of healthcare spending in the UAE, driven by mandatory health insurance regulations in Abu Dhabi and Dubai, making private hospital groups, pharmacy chains, and insurance formulary committees critical procurement channels alongside public bodies. Multinational distributors and licensed local agents serve as the primary intermediaries for both public and private sector supply chains. Donor-funded procurement channels such as UNICEF, the Global Fund, or USAID play a minimal role given the UAE's high-income status, though the country itself acts as a donor and regional logistics hub for humanitarian health supply chains serving lower-income markets. The UAE government has introduced local manufacturing preference policies under its National Strategy for the Pharmaceutical Industry, offering regulatory incentives, reduced registration fees, and prioritized procurement consideration for products manufactured within the country or through approved technology-transfer partnerships with UAE-based facilities.